C反应蛋白、白细胞介素-6与卒中后血管事件复发:个体参与者数据Meta分析
该研究基于10项前瞻性研究、8420例缺血性卒中/短暂性脑缺血发作患者的个体参与者数据,采用研究内多变量回归及随机效应Meta分析,发现基线hsCRP和IL-6与主要不良心血管事件及卒中复发独立相关,为抗炎治疗二级预防随机试验提供了依据。
要点
- 基线IL-6每升高1个loge单位,校正后MACE风险RR为1.12(95%CI 1.04-1.21)。
- 基线hsCRP每升高1个loge单位,校正后MACE风险RR为1.09(95%CI 1.04-1.15)。
- IL-6最高与最低四分位组比较,校正后MACE风险RR为1.35(95%CI 1.09-1.67)。
核心结论
- 血液炎症标志物与卒中后血管事件复发独立相关,强化了缺血性卒中/TIA后抗炎治疗二级预防随机试验的依据。
研究设计与样本
- 个体参与者数据Meta分析,纳入10项前瞻性研究共8420例缺血性卒中/短暂性脑缺血发作患者,采用研究内多变量回归分析后以随机效应Meta分析合并校正风险比(RR)。
主要发现
- 随访18920人年期间,1407例(16.7%[95%CI 15.9-17.5])发生MACE,1191例(14.1%[95%CI 13.4-14.9])发生卒中复发。
- 双变量分析中,基线IL-6每升高1个loge单位与MACE(RR 1.26[95%CI 1.10-1.43])和卒中复发(RR 1.18[95%CI 1.05-1.32])相关。
- 双变量分析中,基线hsCRP每升高1个loge单位与MACE(RR 1.19[95%CI 1.09-1.29])和卒中复发(RR 1.12[95%CI 1.04-1.21])相关。
- 校正血管危险因素和治疗后,IL-6与MACE(RR 1.12[95%CI 1.04-1.21])及卒中复发(RR 1.09[95%CI 1.00-1.19])保持独立相关,hsCRP与MACE(RR 1.09[95%CI 1.04-1.15])及卒中复发(RR 1.05[95%CI 1.00-1.11])保持独立相关。
- 校正后比较最高与最低四分位组(Q4 vs Q1),IL-6(RR 1.35[95%CI 1.09-1.67])和hsCRP(RR 1.31[95%CI 1.07-1.61])与MACE相关;卒中复发方面IL-6(RR 1.33[95%CI 1.08-1.65])有类似结果,hsCRP(RR 1.16[95%CI 0.93-1.43])未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-inflammatory therapies reduce recurrent vascular events in coronary disease. Existing studies have reported highly conflicting findings for the association of blood inflammatory markers with vascular recurrence after stroke leading to uncertainty about the potential of anti-inflammatory therapies after stroke and no consensus about the utility of measurement of inflammatory markers in current guidelines. METHODS: We investigated the association between hsCRP (high-sensitivity C-reactive protein), IL-6 (interluekin-6), and recurrent major adverse cardiovascular events (MACE), and stroke from individual participant data from 8420 patients with ischemic stroke/transient ischemic attack from 10 prospective studies. We did within-study multivariable regression analyses and then combined adjusted risk ratio (RR) by random-effects meta-analysis. RESULTS: During 18 920 person-years of follow-up, 1407 (16.7% [95% CI, 15.9-17.5]) patients had MACE and 1191 (14.1% [95% CI, 13.4-14.9]) patients had recurrent stroke. On bivariate analysis, baseline IL-6 was associated with MACE (RR, 1.26 [95% CI, 1.10-1.43]) and recurrent stroke (RR, 1.18 [95% CI, 1.05-1.32]), per unit increase logeIL-6. Similar associations were observed for hsCRP (MACE RR, 1.19 [95% CI, 1.09-1.29]; recurrent stroke RR, 1.12 [95% CI, 1.04-1.21], per unit increase logehsCRP). After adjustment for vascular risk factors and treatment, independent associations remained with MACE (IL-6, RR, 1.12 [95% CI, 1.04-1.21]; hsCRP, RR, 1.09 [95% CI, 1.04-1.15]) and recurrent stroke (IL-6, RR, 1.09 [95% CI, 1.00-1.19]; hsCRP, RR, 1.05 [95% CI, 1.00-1.11]). Comparing the top with the bottom quarters (Q4 versus Q1), IL-6 (RR, 1.35 [95% CI, 1.09-1.67]) and hsCRP (RR, 1.31 [95% CI, 1.07-1.61]) were associated with MACE after adjustment. Similar results were observed for recurrent stroke for IL-6 (RR, 1.33 [95% CI, 1.08-1.65]) but not hsCRP (RR, 1.16 [95% CI, 0.93-1.43]). CONCLUSIONS: Blood markers of inflammation were independently associated with vascular recurrence after stroke, strengthening the rationale for randomized trials of anti-inflammatory therapies for secondary prevention after ischemic stroke/TIA.
引用
- McCabe JJ, Walsh C, Gorey S, et al. C-Reactive Protein, Interleukin-6, and Vascular Recurrence After Stroke: An Individual Participant Data Meta-Analysis. Stroke. 2023. PMID: 37026458. doi:10.1161/STROKEAHA.122.040529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。